Everything below concerns peptide backbone. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-04-09. Numbers and descriptions here follow the published literature rather than marketing material.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
=== In eukaryotes === As with any protein or RNA, rRNA production is prone to errors resulting in the production of non-functional rRNA. To correct this, the cell allows for degradation of rRNA through the non-functional rRNA decay (NRD) pathway. Much of the research in this topic was conducted on eukaryotic cells, specifically Saccharomyces cerevisiae yeast. Currently, only a basic understanding of how cells are able to target functionally defective ribosomes for ubiquination and degradation in eukaryotes is available.
== Refining the techniques == The next development was gas chromatography (GC). Martin and Synge had predicted its principles in their 1941 paper. Erika Cremer laid the theoretical basis of GC in 1944. Austrian chemist Fritz Prior, under the direction of Erika Cremer, constructed in 1947 the first prototype of a gas chromatograph and achieved separating oxygen and carbon dioxide, in 1947 during his Ph.D. research. Beginning in 1949, Martin and Anthony T. James worked on developing GC. At his 1952 Nobel lecture, Martin announced the successful separation of a wide variety of natural compounds by GC. GC was quickly adopted since it is easy and efficient for separating organic chemicals, and new detection methods for analyzing the output were quickly developed. The thermal conductivity detector, described in 1954 by N. H. Ray, was the foundation for several other methods: the flame ionization detector by J. Harley, W. Nel, and V. Pretorius in 1958, and the electron capture detector by James Lovelock in 1958. Others introduced mass spectrometers to gas chromatography in the late 1950s. The work of Martin and Synge also set the stage for high performance liquid chromatography (HPLC), suggesting that small sorbent particles and pressure could produce fast liquid chromatography techniques. This became widely practical by the late 1960s (and the method was used to separate amino acids as early as 1960).
== Research == Compared to the disease burden of migraine, the amount of healthy life years lost, the field is severely underfunded. In the US in 2019, migraine research got just 7.8% of the funding expected based on its burden. In Europe, it was the most underfunded brain disease when compared to its economic impact.
Necrophages and their microbiotas ("friendly bacteria") produce several molecules of medical interest. These include molecules that can bind to bacterial pathogens (e.g. lectins), inhibit pathogen growth (e.g. chitin, cyclic lipopeptides), and kill pathogens (e.g. antimicrobial peptides, lysozymes). In nature, these molecules are thought to block pathogen entry into the integuments (e.g. skin, cuticle) and circulatory systems (e.g. blood, hemolymph) of necrophages, and enable the immune systems of necrophages to detect, inhibit and kill any pathogens that breach these barriers. Research is underway in Germany, China, the USA and other countries to develop these molecules for use in medicine. Possible applications include antimicrobial wound dressings, antibacterial drugs, and drug delivery systems for bacterial infections.
== Resin types == While the main type of resins used are based on epoxy resin, vinyl ester-based prepregs are also available. Since vinyl ester resins must be pre-accelerated with amine accelerator or cobalt, their processing time at room temperature is shorter than with epoxy-based prepregs. Catalysts (also called hardeners) include peroxides such as methyl ethyl ketone peroxide (MEKP), acetyl acetone peroxide (AAP) or cyclohexanone peroxide (CHP). Vinyl ester resin is used under high impact stress.
Sources: en.wikipedia.org
Organized crime refers to groups of centralized enterprises that engage in, and aim to profit from, illegal activities. Some forms of organized crime exist simply to meet demand for illegal goods or to facilitate trade in products and services banned by the state, such as illegal drugs or firearms. In other cases, criminal organizations force people to do business with them, as when gangs extort protection money from shopkeepers. In the United States, the Organized Crime Control Act (1970) defines organized crime as "[t]he unlawful activities of [...] a highly organized, disciplined association [...]". Criminal activity as a structured process is referred to as racketeering. In the UK, police estimate that organized crime involves up to 38,000 people operating in 6,000 various groups. Historically, the largest organized crime force in the United States has been Cosa Nostra (Italian-American Mafia), but other transnational criminal organizations have also risen in prominence in recent decades. A 2012 article in a U.S. Department of Justice journal stated that: "Since the end of the Cold War, organized crime groups from Russia, China, Italy, Nigeria, and Japan have increased their international presence and worldwide networks or have become involved in more transnational criminal activities.
A spider positioned in the middle of the web makes for a highly visible prey for birds and other predators, even without web decorations; many day-hunting orb-web spinners reduce this risk by hiding at the edge of the web with one foot on a signal line from the hub or by appearing to be inedible or unappetizing. Spiders do not usually adhere to their own webs, because they are able to spin both sticky and non-sticky types of silk, and are careful to travel across only non-sticky portions of the web. However, they are not immune to their own glue. Some of the strands of the web are sticky, and others are not. For example, if a spider has chosen to wait along the outer edges of its web, it may spin a non-sticky prey or signal line to the web hub to monitor web movement. However, in the course of spinning sticky strands, spiders have to touch these sticky strands. They do this without sticking by using careful movements, dense hairs and nonstick coatings on their feet to prevent adhesion.
PDBsum has links to three-dimensional structures of various alcohol dehydrogenases contained in the Protein Data Bank ExPASy contains links to the alcohol dehydrogenase sequences in Swiss-Prot, to a Medline literature search about the enzyme, and to entries in other databases. PDBe-KB provides an overview of all the structure information available in the PDB for Alcohol dehydrogenase 1A. PDBe-KB provides an overview of all the structure information available in the PDB for Alcohol dehydrogenase 1B. PDBe-KB provides an overview of all the structure information available in the PDB for Alcohol dehydrogenase 1C. PDBe-KB provides an overview of all the structure information available in the PDB for Alcohol dehydrogenase 4. PDBe-KB provides an overview of all the structure information available in the PDB for Alcohol dehydrogenase class-3.
The reign of the young Władysław III (1434–44), who succeeded his father Władysław II Jagiełło and ruled as king of Poland and Hungary, was cut short by his death at the Battle of Varna, during a crusade against the Ottoman Empire. This disaster led to an interregnum of three years that ended with the accession of Władysław's brother Casimir IV Jagiellon in 1447. Critical developments of the Jagiellonian period were concentrated during Casimir IV's long reign, which lasted until 1492. In 1454, Royal Prussia was incorporated by Poland and the Thirteen Years' War of 1454–66 with the Teutonic state ensued. In 1466, the milestone Peace of Thorn was concluded. This treaty divided Prussia to create East Prussia, the future Duchy of Prussia, a separate entity that functioned as a fief of Poland under the administration of the Teutonic Knights. Poland also confronted the Ottoman Empire and the Crimean Tatars in the south, and in the east helped Lithuania fight the Grand Duchy of Moscow. The country was developing as a feudal state, with a predominantly agricultural economy and an increasingly dominant landed nobility. Kraków, the royal capital, was turning into a major academic and cultural center, and in 1473 the first printing press began operating there. With the growing importance of szlachta (middle and lower nobility), the king's council evolved to become by 1493 a bicameral General Sejm (parliament) that no longer represented exclusively top dignitaries of the realm.
Sources: en.wikipedia.org
These neurosteroid metabolites of progesterone have relatively short biological half-lives in circulation. Because of this, there are dramatic and highly supraphysiological spikes in allopregnanolone and pregnanolone concentrations followed by steep declines with each oral intake of progesterone. As such, neurosteroid levels fluctuate substantially (e.g., 15-fold in the case of allopregnanolone) and in an unphysiological manner with oral progesterone therapy. In addition, consumption of food with oral progesterone increases its absorption by 2-fold, and this may also further amplify fluctuations in neurosteroid levels, particularly if food intake with progesterone is not consistent from dose to dose. In contrast to oral administration, parenteral progesterone, such as with vaginal administration, avoids the first-pass effect, and is not associated with supraphysiological levels of neurosteroid metabolites, nor with spikes or marked fluctuations in neurosteroid levels. Parenteral routes can be used instead of oral administration to avoid adverse effects related to neurosteroid fluctuations if they prove to be problematic. Lower doses of oral progesterone (e.g., 100 mg/day) are also associated with relatively reduced formation of neurosteroid metabolites, and may similarly help to alleviate such side effects. In addition, the 5α-reductase inhibitor dutasteride, which blocks the production of allopregnanolone (though not of pregnanolone) from progesterone, has been found to diminish symptoms of premenstrual syndrome.
=== 11 June === The SAF announced its withdrawal from the Libya-Egypt-Sudan border triangle following attacks by the LNA and the RSF the previous day. Eight people were killed by RSF shelling in Abu Shouk IDP camp.
The Accreditation Commission for Health Care (ACHC) is a United States-based non-profit health care accrediting organization. It represents an alternative to the Joint Commission and CHAP, The Community Health Accreditation Program. ACHC was established in 1985 by home care health providers to create an accreditation option which was more focused on the needs of small providers. The process began in Raleigh, North Carolina, with the group incorporated in August 1986. The first accredited organization was awarded certification in January 1987. The company began offering services on a national level in 1996. Today, ACHC offers nineteen accreditation programs, nine of which are CMS approved (Acute Care Hospital, Ambulatory Surgery Center, Clinical Laboratory, Critical Access Hospital, DMEPOS, Home Health, Home Infusion Therapy, Hospice, Renal Dialysis).
The introduction or modification of a protecting group occasionally influences the reactivity of the whole molecule. For example, diagrammed below is an excerpt of the synthesis of an analogue of Mitomycin C by Danishefsky.
Ethanol is produced naturally as a byproduct of the metabolic processes of yeast and hence is present in any yeast habitat, including even endogenously in humans, but it does not cause raised blood alcohol content as seen in the rare medical condition auto-brewery syndrome (ABS). It is manufactured through hydration of ethylene or by brewing via fermentation of sugars with yeast (most commonly Saccharomyces cerevisiae). The sugars are commonly obtained from sources like steeped cereal grains (e.g., barley), grape juice, and sugarcane products (e.g., molasses, sugarcane juice). Ethanol–water mixture which can be further purified via distillation.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.